Pancreatic Cancer Research

ResearcherKansai Medical UniversityActive in the last 2 years

Ann‐Lii Cheng

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-9152-6512; OpenAlex author ID A5017953971. Sources: OpenAlex.

Their work

Papers
14 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
0
Collaborators
41
Papers, trials and grants by year

2011: 2 papers · 2012: none · 2013: 2 papers · 2014: none · 2015: none · 2016: 2 papers · 2017: 3 papers · 2018: 1 paper · 2019: none · 2020: 1 paper · 2021: 2 papers · 2022: none · 2023: none · 2024: 1 paper

Papers 14

  1. Adding-on nivolumab to chemotherapy-stabilized patients is associated with improved survival in advanced pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00262-024-03821-3↗
  2. Negative prognostic implications of splenomegaly in nivolumab-treated advanced or recurrent pancreatic adenocarcinoma. Co-author DOI 10.1080/2162402x.2021.1973710↗
  3. Contribution of nuclear BCL10 expression to tumor progression and poor prognosis of advanced and/or metastatic pancreatic ductal adenocarcinoma by activating N… Co-author DOI 10.1186/s12935-021-02143-z↗
  4. Low-dose nab-paclitaxel-based combination chemotherapy in heavily pretreated pancreatic cancer patients. Co-author DOI 10.1016/j.jfma.2019.01.015↗
  5. A Phase I Study of S-1-based Concurrent Chemoradiotherapy Followed by Gemcitabine and S-1 in Metastatic Pancreatic Adenocarcinoma. Co-author DOI 10.21873/anticanres.12790↗
  6. Updated results from GEST study: a randomized, three-arm phase III study for advanced pancreatic cancer. Co-author DOI 10.1007/s00432-017-2349-y↗
  7. Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic panc… Co-author DOI 10.1136/esmoopen-2016-000151↗
  8. Association of MDM2 expression with shorter progression-free survival and overall survival in patients with advanced pancreatic cancer treated with gemcitabine… Co-author DOI 10.1371/journal.pone.0180628↗
  9. Association of radiotherapy with favorable prognosis in daily clinical practice for treatment of locally advanced and metastatic pancreatic cancer. Co-author DOI 10.1111/jgh.13395↗
  10. Perspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancer. Co-author DOI 10.3748/wjg.v22.i32.7275↗
  11. Nuclear expression of glioma-associated oncogene homolog 1 and nuclear factor-κB is associated with a poor prognosis of pancreatic cancer. Last author DOI 10.1159/000353452↗
  12. Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan… Co-author DOI 10.1200/jco.2012.43.3680↗
  13. Induction chemotherapy with gemcitabine, oxaliplatin, and 5-fluorouracil/leucovorin followed by concomitant chemoradiotherapy in patients with locally advanced… Co-author DOI 10.1016/j.ijrobp.2010.10.034↗
  14. Inferior survival of advanced pancreatic cancer patients who received gemcitabine-based chemotherapy but did not participate in clinical trials. Last author DOI 10.1159/000330817↗

Closest collaborators

The 25 strongest of 41 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Sung‐Hsin Kuo · 10 shared papers, 2011–2024 · strength 0.99
  2. Shih‐Hung Yang · 10 shared papers, 2011–2024 · strength 0.99
  3. Yu‐Wen Tien · 10 shared papers, 2011–2024 · strength 0.92
  4. Kun‐Huei Yeh · 7 shared papers, 2016–2024 · strength 0.84
  5. Bang‐Bin Chen · 2 shared papers, 2021–2024 · strength 0.35
  6. Jhe‐Cyuan Guo · 4 shared papers, 2016–2020 · strength 0.33
  7. Ting‐Chun Kuo · 3 shared papers, 2016–2021 · strength 0.26
  8. Yan‐Shen Shan · 2 shared papers, 2011–2024 · strength 0.24
  9. Shinichi Ohkawa · 3 shared papers, 2013–2017 · strength 0.13
  10. Taketo Yamaguchi · 3 shared papers, 2013–2017 · strength 0.13
  11. Takashi Hatori · 3 shared papers, 2013–2017 · strength 0.13
  12. Tatsuya Ioka · 3 shared papers, 2013–2017 · strength 0.13
  13. Shinichi Egawa · 3 shared papers, 2013–2017 · strength 0.13
  14. Narikazu Boku · 3 shared papers, 2013–2017 · strength 0.13
  15. Akihiro Funakoshi · 3 shared papers, 2013–2017 · strength 0.13
  16. Junji Furuse · 3 shared papers, 2013–2017 · strength 0.13
  17. Yasuo Ohashi · 3 shared papers, 2013–2017 · strength 0.13
  18. Masao Tanaka · 3 shared papers, 2013–2017 · strength 0.13
  19. Takuji Okusaka · 3 shared papers, 2013–2017 · strength 0.13
  20. Kenji Yamao · 3 shared papers, 2013–2017 · strength 0.13
  21. Li‐Yuan Bai · 1 shared paper, 2021 · strength 0.13
  22. Atsushi Satō · 2 shared papers, 2013–2017 · strength 0.08
  23. Hideki Ueno · 2 shared papers, 2013–2017 · strength 0.08
  24. Hsu Wu · 1 shared paper, 2016 · strength 0.06
  25. Yasuhiro Hagiwara · 1 shared paper, 2017 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.